A phase II study of TZ-101 in pediatric cancer patients undergoing cord blood stem cell transplantation for the treatment of hematologic alignancies

Trial Profile

A phase II study of TZ-101 in pediatric cancer patients undergoing cord blood stem cell transplantation for the treatment of hematologic alignancies

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs TZ 101 (Primary)
  • Indications Graft-versus-host disease; Haematological malignancies
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Mar 2017 New trial record
    • 06 Mar 2017 According to a Targazyme media release, the U.S. Food and Drug Administration (FDA) has granted IND Clearance to begin enrolling patients in the study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top